QUOTE AND NEWS
FiercePharma  May 24  Comment 
Sanofi has been publicly chastised by lawmakers and public health groups for its proposed Zika vaccine deal with the U.S. Army. Now, an executive is explaining the rationale behind the company’s development plan and defending against claims his...
FierceBiotech  May 24  Comment 
Pierre Fabre, the second biggest biopharma in France (after Big Pharma Sanofi), is boosting its cancer pipeline with what it is dubbing “promising” immuno-oncology candidates from California’s Igenica Biotherapeutics.
GenEng News  May 23  Comment 
The FDA approved Sanofi and Regeneron Pharmaceuticals’ interleukin-6 receptor (IL-6R)-targeting monoclonal antibody (mAb) Kevzara ® (sarilumab) for treating adults with moderately to severely active rheumatoid arthritis (RA) who are intolerant...
FiercePharma  May 22  Comment 
Sanofi and Regeneron just added their second building block to a nascent immunology franchise expected to bring in $5 billion or more by 2022. But to get there, their new Kevzara will have to go up against a host of other rheumatoid arthritis...
Benzinga  May 22  Comment 
At the end of April, biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the FDA had accepted the resubmission of its Biologics License Application (BLA) for a drug called Kevzara. The acceptance qualified the application...
FiercePharma  May 22  Comment 
As a variety of states weigh measures targeting pharmaceutical pricing, Nevada’s Senate has passed a tough new bill that would publicly spotlight insulin makers' price hikes and profits.
FiercePharma  May 17  Comment 
Sanofi got more than it bargained for when it teamed up with the U.S. Army to develop a Zika shot. The company's forthcoming license on the vaccine—whose R&D was partly funded by taxpayers—has triggered a backlash, with nonprofits and...
FiercePharma  May 16  Comment 
With complex biologics making up a growing part of pipelines, drugmakers have been selling or closing small-molecule plants left and right. Sanofi is taking that process a couple of steps further. It will demolish a plant it spent about $118...




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki